Please login to the form below

Not currently logged in
Email:
Password:

Brintellix

This page shows the latest Brintellix news and features for those working in and with pharma, biotech and healthcare.

Surging sales of Lundbeck's CNS drugs assist recovery

Surging sales of Lundbeck's CNS drugs assist recovery

Since its former blockbuster Cipralex (escitalopram) started to succumb to generic competition, Lundbeck has looked to two newer antidepressants - Brintellix/Trintellix (vortioxetine) and Rexulti (brexpiprazole) - to step in and fill the ... breach.

Latest news

  • SMC gives green light for BMS’ Opdivo SMC gives green light for BMS’ Opdivo

    2014. Additionally, the SMC gave three further approvals to Lundbeck's antidepressant Brintellix (vortioxetine), Novartis' Cosentyx (secukinumab) for ankylosing spondylitis, and UCB's Briviact (brivaracetam) for partial-onset seizures in epilepsy

  • Lundbeck sways NICE with new Brintellix data Lundbeck sways NICE with new Brintellix data

    NICE has recommended Lundbeck's Brintellix for adults with major depressive order in final draft guidance. ... The submission included data from the REVIVE trial which compared Brintellix with Servier's Valdoxan (agomelatine).

  • Lundbeck to cut 1,000 jobs in major restructure Lundbeck to cut 1,000 jobs in major restructure

    Lundbeck's focus will now turn more to its newer drugs such as Brintellix (vortioxetine), Northera (droxidopa), Onfi (clobazam) and Abilify Maintena (aripriprazole) which saw a 190% growth in sales.

  • US filing aims to elevate Brintellix above its competition US filing aims to elevate Brintellix above its competition

    US filing aims to elevate Brintellix above its competition. Drug looking for an edge in the highly competitive major depressive disorder market. ... Lundbeck and Takeda have filed for US approval of new labelling for their antidepressant Brintellix that

  • Lundbeck and Otsuka's Rexulti set for August launch in US Lundbeck and Otsuka's Rexulti set for August launch in US

    Meanwhile, Rexulti is one of string of new drugs at Lundbeck - along with the likes of long-acting aripiprazole depot Abilify Maintena (also partnered with Otsuka) and new antidepressant Brintellix (vortioxetine) -

More from news
Approximately 9 fully matching, plus 19 partially matching documents found.

Latest appointments

  • Bayer’s Barbara Jaszewski joins Lundbeck Bayer’s Barbara Jaszewski joins Lundbeck

    In addition, Lundbeck also has Brintellix (vortioxetine) under review by the EMA, while a once-monthly version of schizophrenia drug Abilify (aripiprazole) is also due to launch during 2013.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HealthCircle Communications

Hello. We’re HealthCircle - a multi-channel healthcare communications agency with offices in London, New York and Singapore who offer a...

Latest intelligence

Understanding the chronic disease patient journey in emerging markets
...
Infographic: Keeping tracking on track
Our best practice approach to tracking studies....
What does the Five Year Forward View mean for pharma?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services....

Infographics